Novartis-JPM-20240108.pdf

1、Novartis Strategy&Growth Update Vas Narasimhan,CEOJ.P.Morgan Healthcare ConferenceJanuary 8,2024DisclaimerNovartis Strategy&Growth Update|January 8,2024This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995.Forwa

2、rd-looking statements can generally be identified by words such as“potential,”“can,”“will,”“plan,”“may,”“could,”“would,”“expect,”“anticipate,”“seek,”“look forward,”“believe,”“committed,”“investigational,”“pipeline,”“launch,”or similar terms,or by express or implied discussions regarding potential ma

3、rketing approvals,new indications or labeling for the investigational or approved products described in this presentation;or regarding potential future revenues from such products;or regarding our transformation into a pure-play innovative medicines company;or regarding our mid-term sales guidance;o

4、r regarding our focused pipeline;or regarding potential future,pending or announced transactions;or regarding our approximate estimated peak sales,sales potential and other financial information;or regarding our focus on material environmental,social and governance factors that drive value;or regard

5、ing our commitment to operational excellence;or regarding our expanding use of our technology platforms across core therapeutic areas;or by discussions of strategy,plans,expectations or intentions.You should not place undue reliance on these statements.Such forward-looking statements are based on ou

6、r current beliefs and expectations regarding future events,and are subject to significant known and unknown risks and uncertainties.Should one or more of these risks or uncertainties materialize,or should underlying assumptions prove incorrect,actual results may vary materially from those set forth